See Shionogi-Sponsored Publications

Publications

Here, you can review available Shionogi-sponsored publications. If you would like an electronic copy of one of the journal publications on this page, please contact
Shionogi Medical Information for further assistance.

Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses of products will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

  • All
  • Cefiderocol
  • Edaravone
  • Ensitrelvir
  • Zatolmilast
  • All
  • In vitro
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Real-world evidence
  • Surveillance
  • Review
  • Pharmacokinetics/Pharmaco-dynamics
  • Compatibility
  • All
  • Amyotrophic Lateral Sclerosis (ALS)
  • COVID-19
  • Fragile X syndrome
  • Gram-negative infection
 
Ensitrelvir
Pharmacokinetics/Pharmacodynamics
COVID-19

Utility of coproporphyrin-I determination in first-in-human study for early evaluation of OATP1B inhibitory potential based on investigation of ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor

Published:
2024
Authors:
Watari R, Sawada H, Hashimoto H, et al.
View Publication
 
Ensitrelvir
Phase 1
Pharmacokinetics/Pharmacodynamics
COVID-19

A phase 1 study of ensitrelvir fumaric acid tablets evaluating the safety, pharmacokinetics and food effect in healthy adult populations

Published:
2023
Authors:
Shimizu R, Sonoyama T, Fukuhara T, et al.
View Publication
 
Cefiderocol
Phase 4
Real-world evidence
Gram-negative infection

Carbapenem-resistant Acinetobacter spp infection in critically ill patients with limited treatment options: a descriptive study of cefiderocol therapy during the COVID-19 pandemic

Published:
2023
Authors:
Giannella M, Verardi S, Karas A, et al.
View Publication
 
Cefiderocol
Compatibility
Gram-negative infection

Cefiderocol for injection: compatibility testing using the MINI-BAG plus container system and the VIAL-MATE adaptor

Published:
2023
Authors:
Rathod D, Chen Z, Slover CM, et al.
View Publication
 
Cefiderocol
Phase 4
Real-world evidence
Gram-negative infection

Cefiderocol treatment for patients with multidrug- and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program

Published:
2023
Authors:
Satlin MJ, Simner PJ, Slover CM, et al.
View Publication